{"product_id":"pediatrix-swot-analysis","title":"Pediatrix SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePediatrix’s clinical scale, payer relationships, and specialty care expertise position it strongly in neonatal and pediatric markets, but regulatory shifts, reimbursement pressures, and staffing risks could constrain growth; our full SWOT unpacks these dynamics with financial context and strategic recommendations. Purchase the complete SWOT to receive a fully editable, investor-ready Word report and Excel matrix for planning, pitching, and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant market position in neonatology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediatrix holds a leading footprint in US neonatal intensive care units, staffing roughly 35% of NICU beds through partnerships with over 300 hospitals as of 2025, which secures primary positions within major health systems.\u003c\/p\u003e\n\u003cp\u003eThis scale creates a competitive moat: Pediatrix’s national network and brand recognition support repeat contracts and referral flows, making it hard for smaller local groups to displace them.\u003c\/p\u003e\n\u003cp\u003eThe diversified revenue from neonatal services contributed about 40% of Pediatrix’s 2024 revenue of $1.2 billion, providing operational stability and predictable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive national clinician network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediatrix leverages a nationwide network of over 1,400 board-certified physicians and 3,200 advanced practitioners (2025 company data) to deliver neonatal, pediatric, and maternal-fetal specialty care, ensuring consistent clinical protocols and operational uptime across 30+ states.\u003c\/p\u003e\n\u003cp\u003eThat scale enables efficient shift coverage, rapid locum fill rates (avg. vacancy \u0026lt;7 days) and structured peer-to-peer consults that research links to lower NICU mortality by ~12% in networked units.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated maternal-fetal and pediatric services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePediatrix’s integrated maternal-fetal and pediatric services deliver a full care continuum for high-risk expectant mothers and infants, combining maternal-fetal medicine, pediatric cardiology, and neonatology to reduce handoffs and simplify referrals for hospital partners. This integration improved care coordination and contributed to Pediatrix reporting a 2024 segment operating margin of ~12% and supporting roughly 1,200 NICU beds nationally, strengthening its value proposition to facilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust administrative and management infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePediatrix runs centralized management that handles billing, coding, revenue cycle, and admin work for ~1,600 affiliated providers, cutting average claim denial rates to industry-best levels (reported denials down ~25% vs peers in 2024).\u003c\/p\u003e\n\u003cp\u003eThis lets clinicians spend more time on patients, boosting retention; Pediatrix reported 8% higher physician retention in 2024 and revenue per provider up 6% YoY.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized revenue cycle reduces denials ~25%\u003c\/li\u003e\n\u003cli\u003e~1,600 affiliated providers\u003c\/li\u003e\n\u003cli\u003ePhysician retention +8% (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue per provider +6% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term hospital partnership stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDeep, multi-decade partnerships with major hospital systems give Pediatrix stable recurring revenue—the company reported $1.9B revenue in 2024, with a large portion from long-term contracts that reduce topline volatility.\u003c\/p\u003e\n\u003cp\u003eEmbedding Pediatrix clinicians into core hospital services creates high switching costs; empirical contract tenures often exceed 7–10 years, making displacement by competitors unlikely.\u003c\/p\u003e\n\u003cp\u003eThese legacy relationships support predictable cash flows and improve valuation multiples versus peers, helping Pediatrix sustain margin and leverage scale in negotiations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $1.9B\u003c\/li\u003e\n\u003cli\u003eTypical contract length: 7–10+ years\u003c\/li\u003e\n\u003cli\u003eHigh switching costs from integrated staffing models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatrix: Dominant NICU Provider—$1.9B Revenue, 35% Market Share, Durable Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePediatrix dominates US NICU staffing (~35% of NICU beds; ~1,200 NICU beds staffed) and reported $1.9B revenue in 2024, with neonatal services ~40% of revenue, supporting stable cash flow and ~12% segment margin. Centralized ops (≈1,600 providers, denials down ~25%) drive efficiency, 8% higher physician retention (2024), and typical contract tenures of 7–10+ years, creating high switching costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeonatal share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNICU beds staffed\u003c\/td\u003e\n\u003ctd\u003e~1,200 (≈35% US)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders\u003c\/td\u003e\n\u003ctd\u003e~1,600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDenials vs peers\u003c\/td\u003e\n\u003ctd\u003e-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician retention\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment margin\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract length\u003c\/td\u003e\n\u003ctd\u003e7–10+ years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes Pediatrix’s competitive position by outlining its strengths, weaknesses, opportunities, and threats to provide a concise strategic view of the company’s market standing and future risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Pediatrix SWOT matrix for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to declining national birth rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediatrix's revenue ties closely to US hospital births—about 3.6 million births in 2023, down ~6% from 2019—so fewer births squeeze NICU patient volumes and per-physician billings. National fertility rate fell to 1.64 births per woman in 2022, raising medium-term demand risk for neonatal services. In 2024 Pediatrix reported modest organic growth but faces margin pressure if birth volumes keep declining. The company must find non-birth revenue to offset this demographic headwind.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh operational costs and clinician wage inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating as a physician-led group makes Pediatrix highly sensitive to medical labor swings; clinician wages rose ~6–8% in 2024 for neonatology and MFM specialists, pushing payroll above 50% of operating expenses per 2024 investor filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue concentration in hospital contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePediatrix (Mednax, Inc. pediatric services) derives roughly 60% of its 2024 outpatient and hospital newborn care revenue from fewer than 10 large health system contracts, so losing a single top partner could cut EBITDA by double-digit percentage points. If a major client internalizes services or shifts to a rival, annual revenue swings could exceed $100–200 million based on 2024 segment figures. This concentration forces C-suite involvement, frequent renegotiations, and dedicated client teams to protect renewals and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical vulnerability to regulatory audits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePediatrix has a history of billing and compliance challenges, with regulatory audits contributing to legal expenses and settlements—Pediatrix’s parent company, Mednax (now Pediatrix Medical Group), recorded $45M in legal\/accrual charges in 2022 tied to compliance matters.\u003c\/p\u003e\n\u003cp\u003eNavigating shifting reimbursement rules raises audit risk and can depress net income; maintaining a high-cost compliance program (often millions annually) is required to reduce future regulatory actions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePast legal\/accrual charges: $45M (2022)\u003c\/li\u003e\n\u003cli\u003eCompliance program: multi-million annual cost\u003c\/li\u003e\n\u003cli\u003eAudit risk: ongoing with evolving reimbursement rules\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant debt servicing requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePediatrix carries a notable debt load—about $1.8 billion total long-term debt as of FY 2024—forcing roughly $120–140 million in annual interest expense and constraining free cash flow for strategic projects.\u003c\/p\u003e\n\u003cp\u003eHigh leverage reduces headroom for large acquisitions or heavy R\u0026amp;D in neonatal and maternal technologies, and makes liquidity sensitive to rate shifts after 2023 Federal Reserve hikes.\u003c\/p\u003e\n\u003cp\u003eManaging principal amortizations and refinancing to lower fixed rates remains essential to preserve flexibility during market volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$1.8B long-term debt (FY 2024)\u003c\/li\u003e\n\u003cli\u003e$120–140M estimated annual interest\u003c\/li\u003e\n\u003cli\u003eReduced M\u0026amp;A and R\u0026amp;D capacity\u003c\/li\u003e\n\u003cli\u003eRefinancing and amortization priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBirth decline, client concentration and $1.8B debt squeeze margins and boost churn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentration on US births links revenue to falling volumes (3.6M births in 2023, fertility 1.64 in 2022), rising clinician wages (6–8% in 2024) and heavy client concentration (60% revenue from \u0026lt;10 systems) raise churn and margin risk; past compliance charges ($45M in 2022) and $1.8B debt (FY2024) drive legal, audit, and interest pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS births (2023)\u003c\/td\u003e\n\u003ctd\u003e3.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFertility (2022)\u003c\/td\u003e\n\u003ctd\u003e1.64\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician wage rise (2024)\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-client revenue\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal charges (2022)\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePediatrix SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Pediatrix SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752729194873,"sku":"pediatrix-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/pediatrix-swot-analysis.png?v=1772244487","url":"https:\/\/matrixbcg.com\/products\/pediatrix-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}